{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:41:12Z","timestamp":1761648072697},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To assess the therapeutic response of intravenous (IV) pulse cyclophosphamide therapy in polymyositis and dermatomyositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data of 9 patients (M:F = 2:7) who received IV pulse cyclophosphamide therapy were retrospectively analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean symptom duration was 11.33 \u00b1 10.6 months (range, 2\u201334 months). The cohort comprised (1) primary idiopathic polymyositis (n = 1), (2) primary idiopathic dermatomyositis (n = 1), (3) childhood type associated with vasculitis (n = 1), and (4) associated with collagen vascular disease (n = 6). All patients improved and became clinically asymptomatic after a mean period of 12.33 \u00b1 6.5 months (range, 4\u201324 months); 5 remained asymptomatic at the end of a median follow-up period of 22 months. All patients received concomitant steroid therapy, and in 6, steroids could be tapered after the initiation of IV pulse cyclophosphamide therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this cohort of polymyositis\/dermatomyositis, treatment with IV pulse cyclophosphamide was associated with improvement; the therapeutic response was sustained in majority of the patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0b013e31828ee913","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T18:43:51Z","timestamp":1369334631000},"page":"161-168","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Limitations of Pulse Cyclophosphamide Therapy in Polymyositis and Dermatomyositis"],"prefix":"10.1097","volume":"14","author":[{"given":"M.","family":"Nagappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Taly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gayathri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S.","family":"Bindu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20240808","first-page":"1329","article-title":". Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982.","volume":"17","author":"Oddis","year":"1990","journal-title":"J Rheumatol"},{"key":"R2-1-20240808","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":". Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R3-1-20240808","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.10313","article-title":"Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.","volume":"4","author":"Mastaglia","year":"2003","journal-title":"Muscle Nerve"},{"key":"R4-1-20240808","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts).","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R5-1-20240808","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":", for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.","volume":"72","author":"Merkies","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-1-20240808","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V87.2.491.bloodjournal872491","article-title":"Complete remission in severe aplastic anaemia after high-dose cyclophosphamide without bone marrow transplantation.","volume":"87","author":"Brodsky","year":"1996","journal-title":"Blood"},{"key":"R7-1-20240808","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0140-6736(00)04278-1","article-title":"High-dose cyclophosphamide in aplastic anemia.","volume":"357","author":"Brodsky","year":"2001","journal-title":"Lancet"},{"key":"R8-1-20240808","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: rebooting with a high-dose cyclophosphamide.","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"R9-1-20240808","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":". Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-1-20240808","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":". Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.","volume":"26","author":"de Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"R11-1-20240808","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1085-9489.2005.10104.x","article-title":"High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.","volume":"10","author":"Gladstone","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"R12-1-20240808","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.21226","article-title":". Primary central nervous system vasculitis: analysis of 101 patients.","volume":"62","author":"Salvarani","year":"2007","journal-title":"Ann Neurol"},{"key":"R13-1-20240808","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(89)92416-1","article-title":". Cyclophosphamide in severe polymyositis.","volume":"1","author":"Bombardieri","year":"1989","journal-title":"Lancet"},{"key":"R14-1-20240808","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":". A computer assisted analysis of 153 paients with polymyositis and dermatomyositis.","volume":"86","author":"Bohan","year":"1977","journal-title":"Medicine"},{"key":"R15-1-20240808","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0404.1982.tb03087.x","article-title":"Polymyositistreatment and prognosis.","volume":"65","author":"Henricksson","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"R16-1-20240808","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/brain\/89.4.747","article-title":"Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis.","volume":"89","author":"Rose","year":"1966","journal-title":"Brain"},{"key":"R17-1-20240808","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":". Azathioprine with prednisone for polymyositis: a controlled, clinical trial.","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"R18-1-20240808","first-page":"A321","article-title":"Intermittent, high dose, intravenous glucocorticoid (GC) treatment (Rx) is preferred to high dose oral GC administration in adult dermatomyositis (DM).","volume":"48","author":"Genge","year":"1997","journal-title":"Neurology"},{"key":"R19-1-20240808","first-page":"1225","article-title":". The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy.","volume":"16","author":"Cronin","year":"1989","journal-title":"J Rheumatol"},{"key":"R20-1-20240808","first-page":"309","article-title":". Effective cyclophosphamide pulse therapy for an young infant with severe dermatomyositis.","volume":"43","author":"Senju","year":"2011","journal-title":"Article in Japanese No To Hattatsu"},{"key":"R21-1-20240808","first-page":"895","article-title":". Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis.","volume":"42","author":"Nakashima","year":"2002","journal-title":"Article in Japanese Ryumachi"},{"key":"R22-1-20240808","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/039463200601900424","article-title":". Successful salvage therapy of intravenous cyclophosphamide for refractory polymyositis in an elderly patient: case report.","volume":"19","author":"Pinto","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R23-1-20240808","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2169\/internalmedicine.47.1289","article-title":"Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy.","volume":"47","author":"Tsujimura","year":"2008","journal-title":"Intern Med"},{"key":"R24-1-20240808","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","article-title":". Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.","volume":"43","author":"Riley","year":"2004","journal-title":"Rheumatology"},{"key":"R25-1-20240808","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard.2007.077446","article-title":". High-dose cyclophosphamide without stem cell rescue in scleroderma.","volume":"67","author":"Tehlirian","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R26-1-20240808","first-page":"256","article-title":". Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopatic inflammatory myopathy.","volume":"135","author":"Garcia-Hernandez","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"R27-1-20240808","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2332\/allergolint.55.199","article-title":". Successful treatment with regimen of intravenous gammaglobulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis.","volume":"55","author":"Murota","year":"2006","journal-title":"Allergol Int"},{"key":"R28-1-20240808","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01526181","article-title":"Complications of cyclophosphamide therapy.","volume":"254","author":"Langford","year":"1997","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R29-1-20240808","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"; European Vasculitis Study Group. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"R30-1-20240808","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":", on behalf of EUVAS Investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R31-1-20240808","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis.","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201306000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:11:15Z","timestamp":1723158675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201306000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e31828ee913","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}